Genesis Healthcare Inc. (GEN)

1.39
0.21 17.80
NYSE : Health Services
Prev Close 1.18
Open 1.18
Day Low/High 1.17 / 1.52
52 Wk Low/High 0.60 / 3.97
Volume 2.40M
Avg Volume 530.00K
Exchange NYSE
Shares Outstanding 94.10M
Market Cap 159.53M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Felicia Chew Of Genesis Rehab Services Approved As Co-Principal Investigator In $4.7 Million Funding Award

Felicia Chew Of Genesis Rehab Services Approved As Co-Principal Investigator In $4.7 Million Funding Award

Contract funded by the Patient-Centered Outcomes Research Institute to Study Treatment Approaches for Nursing Home Residents with Dementia

Genmab And Seattle Genetics To Initiate New Study Of Novel Antibody-Drug Conjugate Tisotumab Vedotin In Cervical Cancer

Genmab And Seattle Genetics To Initiate New Study Of Novel Antibody-Drug Conjugate Tisotumab Vedotin In Cervical Cancer

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (NASDAQ: SGEN) announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer.

Short Interest Expands By 29.6% For GEN

Short Interest Expands By 29.6% For GEN

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 657,491 share increase in total short interest for Genesis Healthcare Inc , to 2,874,971, an increase of 29.65% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Genesis Rehab Services Honored By Philadelphia Business Journal As A 2017 Health Care Innovator

Genesis Rehab Services Honored By Philadelphia Business Journal As A 2017 Health Care Innovator

Awards program recognizes region's most innovative companies and doctors

Genesis HealthCare Opens 11th PowerBack Rehabilitation Location

Genesis HealthCare Opens 11th PowerBack Rehabilitation Location

3rd PowerBack Rehabilitation Location in New Jersey

Genmab And Seattle Genetics To Co-develop Tisotumab Vedotin For Solid Tumors

Genmab And Seattle Genetics To Co-develop Tisotumab Vedotin For Solid Tumors

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Seattle Genetics, Inc.

Eight Genesis HealthCare Centers Receive Silver National Quality Award 

Eight Genesis HealthCare Centers Receive Silver National Quality Award 

Centers recognized by national program for commitment to quality care

IIROC Trade Resumption - GEN

IIROC Trade Resumption - GEN

IIROC Trading Halt - GEN

IIROC Trading Halt - GEN

Six Genesis HealthCare Centers Receive Bronze National Quality Award

Centers recognized by national program for commitment to quality care

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGM, CETV, CUBI, DVCR, EC, EOCC, ERI, EVA, FBC, GLPG, HCCI, IGT, LII, LXFR, MSL, RXN, TBK, TEGP, USDP, VIRT, VOXX, WNEB Downgrades: ACY, ATNI, BH, BXP, CREE, CYRN, DISCK, EQR, ESSA, GE, HF, SHLO, SMRT, SSBI, UPLD Initiations: BLBD, GEN, MDGS Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: E+ (Sell)